Free shipping on all orders over $ 500

EDO-S101

Cat. No. M6070

All AbMole products are for research use only, cannot be used for human consumption.

EDO-S101 Structure
Synonym:

Tinostamustine; EDO-S-101; EDO-S 101

Size Price Availability Quantity
5mg USD 210  USD210 In stock
10mg USD 300  USD300 In stock
25mg USD 495  USD495 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

In vitro: EDOS101 inhibits HDAC activity in rat peripheral blood mononuclear cells (PBMCs) in a cellular assay by approximately 90% one hour after dosing with 10mg/kg i.v. HDAC inhibition in PBMCs could not be increased with higher doses up to 50mg/kg. EDO-S101 triggers apoptosis and shows strong antitumor activity in HL60 and Daudi cells. Initial in vitro experiments in HL60 cells shows an activation of the intrinsic pathway of apoptosis with cleavage of caspases 3, 9 and PARP and a marked reduction of anti-apoptotic proteins XIAP and Mcl-1. In vivo: Intracellular HDAC inhibition of EDO-S101, which occurs rapidly after dosing is at maximum activity already at the lowest dose of 10mg/kg and lasts for about 12-16 hours. Exposure to EDO-S101 causes a strong DNA repair response evidenced by activation of pH2AX and p53 in tumors taken from mice bearing subcutaneous human Burkitt’s lymphoma. Tumors of BL rapidly shrink or are completely eradicated after i.v. administration of EDO-S101.

Protocol (for reference only)
Cell Experiment
Cell lines human MM cell lines
Preparation method MM1S cells were incubated for 48 h with increasing doses of EDO-S101, together with IL-6 at 1 nM or IGF-1 at 10 nM, and proliferation of MM cells was assessed by MTT assay.
Concentrations
Incubation time 48 h
Animal Experiment
Animal models Mice
Formulation
Dosages 60 mg/kg
Administration i.v.
Chemical Information
Molecular Weight 415.36
Formula C19H28Cl2N4O2
CAS Number 1236199-60-2
Solubility (25°C) 30 mg/mL in DMSO
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] López-Iglesias AA, et al. J Hematol Oncol. Preclinical anti-myeloma activity of EDO-S101, a new bendamustine-derived molecule with added HDACi activity, through potent DNA damage induction and impairment of DNA repair.

[2] Mehrling T, et al. Anticancer Agents Med Chem. The Alkylating-HDAC Inhibition Fusion Principle: Taking Chemotherapy to the Next Level with the First in Class Molecule EDO-S101.

Related HDAC Products
CM-444

CM-444 is an inhibitor for HDAC and DNA methyltransferases (DNMT) with IC50 values of 6 nM-0.6 μM and 1.8-2.3 μM, respectively. CM-444 is an inducer for the differentiation of acute myeloid leukemia cells. CM-444 exhibits anti-leukemic activity and improves the survival rate in mouse models.

CM-1758

CM-1758 is a histone deacetylase (HDAC) inhibitor. CM-1758 inhibits tumor growth in vivo. CM-1758 induces acetylation of non-histone proteins in acute myeloid leukemia cells.

T-518 

T-518 is an orally active, selective, and blood-brain barrier permeable HDAC6 inhibitor with an IC50 value of 36 nM for human HDAC6.

SE-7552 

SE-7552, a 2-(difluoromethyl)-1,3,4-oxadiazole (DFMO) derivative, is an orally active, highly selective, non-hydroxamate HDAC6 inhibitor with an IC50 of 33 nM.

BRD9757 

BRD9757 is a potent, capless and selective HDAC6 inhibitor with an IC50 of 30 nM.

  Catalog
Abmole Inhibitor Catalog




Keywords: EDO-S101, Tinostamustine; EDO-S-101; EDO-S 101 supplier, HDAC, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.